Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

Author's Avatar
May 27, 2022

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA® (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).